Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Benzgalantamine gluconate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Cognition Launches ZUNVEYL for Mild to Moderate Alzheimer’s
Details : Zunveyl (benzgalantamine gluconate) is a an acetylcholinesterase inhibitor, small molecule drug being evaluated for the treatment of mild to moderate alzheimer’s disease.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Benzgalantamine gluconate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable